Kiniksa Pharmaceuticals Reports Q2 GAAP EPS and Revenue Beat
Kiniksa Pharmaceuticals International, plc (KNSA) reported better-than-expected financial results for its second quarter in 2026. The company's GAAP earnings per share came in at $0.30, surpassing estimates by $0.01. Revenue reached $243.6 million, a significant increase of 55.4% year-over-year and exceeding expectations by approximately $17.14 million. The strong performance was driven largely by its product ARCALYST, which generated net revenue of $243.6 million for the quarter. The results reflect robust demand or pricing power in Kiniksa's core therapeutic areas, potentially signaling continued momentum as it moves forward into 2027.
Tickers: $KNSA
Topics: financial_results pharmaceuticals